Volume 23, Number 11—November 2017
Research Letter
Mycobacterium shimoidei, a Rare Pulmonary Pathogen, Queensland, Australia
Timothy M. Baird
, Robyn Carter, Geoffrey Eather, and Rachel Thomson
, Robyn Carter, Geoffrey Eather, and Rachel Thomson
Table
Clinical characteristics, treatment, and outcomes of Mycobacterium shimoidei isolates, Queensland, Australia*
| Specimen (isolates) | Age, y/sex | Significant | Signs/ symptoms | Radiology | Concurrent conditions | Management (time) | Outcome |
|---|---|---|---|---|---|---|---|
| Sp and Br (×4) | 60/M | Likely | C, Sp, WL | Cavities, nodule | COPD, asthma | Observed | Stable |
| LTis (×1) | 56/M | Likely | Died | Unknown | Unknown | None | Died |
| Sp (×1) | 75/F | Likely | C, Sp, WL | Cavities, nodules | COPD, HF, AF, GERD | None | Died of other cause |
| Sp (×3) | 72/M | Likely | C, D, WL | Cavity, nodules | COPD, bronchiectasis, IHD | Observed | Died of lung disease |
| LTis (×1) | 62/F | Likely | C, WL, NS | Cavity | None | INH, RFP, PZA, EMB (6 mo) | Stable |
| Sp (×2) | 68/M | Likely | C, Sp, H, WL, Fa | Cavities, consolidation | COPD, aspergillus, HTN | CLA, MFX, SMX (12 mo) | Improved |
| Sp and Br (×4) | 70/M | Likely | C, Sp, CP | Cavities | Lung cancer, COPD, bronchiectasis | CLA, RIF, EMB (12 mo) | Died of lung disease |
| LTis (×1) | 77/F | Likely | C, WL, Fa | Cavity, nodules | COPD, GERD | CLA, RFP, EMB (18 mo) | Improved |
| Sp (×3) | 68/M | Likely | C, Sp, WL | Cavity, consolidation | COPD, RA, anemia | Observed | Stable |
| Br (×1) | 76/M | Possibly | D, WL | Nodules | COPD, anemia | None | Unknown |
| Br (×1) | 84/M | Possibly | C, Sp | Mass, effusion | Lung cancer, GERD | Observed | Died of lung disease |
| Sp (×1) | 84/M | Possibly | C, D, Fa | Consolidation | COPD, bronchiectasis | Observed | Improved |
| Sp (×1) | 29/M | Possibly | C, D, WL | Nodules | CF, bronchiectasis | AMK, CFX, AZA, CFZ (24 mo) | Improved |
| Sp (×1) | 74/F | Possibly | C, Sp | Nodules, consolidation | Bronchiectasis | Observed | Improved |
| Sp (×5) | 84/F | Possibly | C, Sp, H, WL | Nodules | Bronchiectasis, type 2 diabetes, HTN | CLA (2 mo) | Improved |
| Sp (×1) | 58/M | Possibly | C, Sp | Normal | Obesity, HTN | Observed | Stable |
| Sp (×1) | 57/M | Unlikely | Unknown | Unknown | Unknown | Unknown | Unknown |
| LTis (×1) | 55/F | Unlikely | Unknown | Unknown | Unknown | Unknown | Unknown |
| Sp (×1) | 67/M | Unlikely | Unknown | Unknown | Unknown | Unknown | Unknown |
| Sp (×1) | 60/M | Unlikely | C, D | Normal | Asthma | None | Unknown |
| Sp (×1) | 59/F | Unlikely | C | Normal | Asthma, GERD | None | Unknown |
| Sp (×1) | 73/M | Unlikely | Unknown | Unknown | Unknown | Unknown | Unknown |
| Sp (×1) | 54/M | Unlikely | Unknown | Unknown | Unknown | Unknown | Unknown |
*AF, atrial fibrillation; AMK, amikacin; AZA, azithromycin; Br, bronchoscopic washing; C, cough; CF, cystic fibrosis; CFX, cefoxitin; CFZ, clofazimine; CLA, clarithromycin; COPD, chronic obstructive pulmonary disease; CP, chest pain; D, dyspnea; EMB, ethambutol; Fa, fatigue; GERD, gastroesophageal reflux disease; H, hemoptysis; HF, heart failure; HTN, hypertension; IHD, ischemic heart disease; INH, isoniazid; LTis, lung tissue; MFX, moxifloxacin; NS, night sweats; PZA, pyrazinamide; RA, rheumatoid arthritis; RFP, rifampin; RIF, rifabutin; SMX, sulfamethoxazole, Sp, sputum; WL, weight loss.
Page created: October 17, 2017
Page updated: October 17, 2017
Page reviewed: October 17, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.